Gastrodin Improves the Activity of the Ubiquitin-Proteasome System and the Autophagy-Lysosome Pathway to Degrade Mutant Huntingtin

• Published in: International journal of molecular sciences Vol. 25; no. 14; p. 7709
• Main Authors: Sun, He, Li, Miao, Li, Yunling, Zheng, Na, Li, Jiaxin, Li, Xiang, Liu, Yingying, Ji, Qianyun, Zhou, Liping, Su, Jingwen, Huang, Wanxu, Liu, Zhongbo, Liu, Peng, Zou, Libo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.07.2024
• Subjects: Animals; Autophagy; Autophagy - drug effects; autophagy–lysosome pathway; Benzyl Alcohols - pharmacology; Enzymes; gastrodin; Glucosides - pharmacology; Huntingtin Protein - genetics; Huntingtin Protein - metabolism; Huntington Disease - drug therapy; Huntington Disease - genetics; Huntington Disease - metabolism; Huntingtons disease; Lysosomes - drug effects; Lysosomes - metabolism; Mice; Morphology; mutant huntingtin protein; Mutation; neurodegeneration; PC12 Cells; Proteasome Endopeptidase Complex - metabolism; Proteins; Proteolysis - drug effects; Rats; Toxicity; Ubiquitin - metabolism; ubiquitin–proteasome system; neurodegeneration; ubiquitin–proteasome system; gastrodin; autophagy–lysosome pathway; mutant huntingtin protein
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25147709

Gastrodin (GAS) is the main chemical component of the traditional Chinese herb (called "Tianma" in Chinese), which has been used to treat neurological conditions, including headaches, epilepsy, stroke, and memory loss. To our knowledge, it is unclear whether GAS has a therapeutic effect on Huntington's disease (HD). In the present study, we evaluated the effect of GAS on the degradation of mutant huntingtin protein (mHtt) by using PC12 cells transfected with N-terminal mHtt Q74. We found that 0.1-100 μM GAS had no effect on the survival rate of Q23 and Q74 PC12 cells after 24-48 h of incubation. The ubiquitin-proteasome system (UPS) is the main system that clears misfolded proteins in eukaryotic cells. Mutated Htt significantly upregulated total ubiquitinated protein (Ub) expression, decreased chymotrypsin-like, trypsin-like and caspase-like peptidase activity, and reduced the colocalization of the 20S proteasome with mHtt. GAS (25 μM) attenuated all of the abovementioned pathological changes, and the regulatory effect of GAS on mHtt was found to be abolished by MG132, a proteasome inhibitor. The autophagy-lysosome pathway (ALP) is another system for misfolded protein degradation. Although GAS downregulated the expression of autophagy markers (LC3II and P62), it increased the colocalization of LC3II with lysosomal associated membrane protein 1 (LAMP1), which indicates that ALP was activated. Moreover, GAS prevented mHtt-induced neuronal damage in PC12 cells. GAS has a selective effect on mHtt in Q74 PC12 cells and has no effect on Q23 and proteins encoded by other genes containing long CAGs, such as Rbm33 (10 CAG repeats) and Hcn1 (>30 CAG repeats). Furthermore, oral administration of 100 mg/kg GAS increased grip strength and attenuated mHtt aggregates in B6-hHTT130-N transgenic mice. This is a high dose (100 mg/kg GAS) when compared with experiments on HD mice with other small molecules. We will design more doses to evaluate the dose-response relationship of the inhibition effect of GAS on mHtt in our next study. In summary, GAS can promote the degradation of mHtt by activating the UPS and ALP, making it a potential therapeutic agent for HD.